Biologics Safety Testing Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Biologics safety testing comprises analytical procedures and quality control measures used to detect contaminants, verify sterility, and confirm the integrity of biologic products throughout development and manufacturing. The market spans instruments, reagents and kits, and outsourced testing services, serving pharmaceutical companies, biotechnology firms, contract research organizations, and academic institutions. With the global biopharmaceutical pipeline increasingly populated by complex modalities such as gene therapies and cell-based treatments, demand for comprehensive safety assessment has escalated significantly.

• •Market valued at $4.98 billion in 2025, with projections ranging from $9.66 billion by 2031 to $14.60 billion by 2033 depending on methodology
• •Testing categories include sterility testing, endotoxin testing, bioburden testing, mycoplasma detection, adventitious agent screening, and cell line characterization
• •Regulatory mandates from the FDA, EMA, and other global health authorities drive mandatory safety testing across all biologic product approvals

The expanding global pipeline of biologic drugs, particularly monoclonal antibodies and advanced therapies, directly fuels demand for safety testing services and consumables. Rising biosimilar development and the growing complexity of novel therapeutics such as CAR-T cell therapies and viral vector vaccines require increasingly sophisticated safety assessments. Additionally, heightened regulatory scrutiny and the shift toward continuous manufacturing processes have intensified testing frequency and scope.

• •Growing R&D expenditure in biotechnology and the rising number of clinical trials for biologic candidates
• •Stringent regulatory requirements governing adventitious agent detection and residual contaminant testing
• •Expansion of contract development and manufacturing organization (CDMO) infrastructure in emerging markets

The market is segmented by offering into instruments, reagents and kits, and services, with services representing the largest segment due to the technical complexity and regulatory expertise required. Test types include adventitious agent detection, bioburden testing, sterility testing, endotoxin testing, and cell line authentication. Geographically, North America dominates with established biopharma hubs, while Asia-Pacific is projected to register the strongest growth rate as China, India, and Singapore expand their biomanufacturing sectors.

• •Services segment leads, driven by outsourced testing demand from small and mid-sized biotech firms lacking in-house capabilities
• •Reagents and kits segment benefits from assay standardization and the shift toward rapid, high-throughput testing platforms
• •Asia-Pacific growth propelled by government investments in biotechnology infrastructure and growing CDMO outsourcing from Western markets

What are the recent trends and outlook?

The market is witnessing a shift toward rapid, automated testing platforms that reduce turnaround times while maintaining regulatory compliance. Growing adoption of advanced analytical technologies, including next-generation sequencing for adventitious agent detection and novel cell-based assays, is reshaping service offerings. As personalized medicine and gene therapies gain regulatory approval, specialized safety testing requirements for these novel modalities are expected to create new revenue streams through 2030.

• •Next-generation sequencing (NGS) is increasingly adopted for viral safety testing due to its broader detection capability compared to traditional methods
• •AI and machine learning integration into data analysis pipelines is improving anomaly detection and reducing false-positive rates in safety assays
• •Consolidation through mergers and acquisitions continues as large players seek to broaden their service capabilities and geographic footprint